【Polaris Pharmaceuticals-KY】Voluntary Withdrawal of BLA for Pegargiminase (ADI-PEG 20) for Malignant Pleural Mesothelioma
NQ Score
48/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Polaris Pharmaceuticals announced on May 25, 2026, that it will voluntarily withdraw its BLA for Pegargiminase (ADI-PEG 20) for the treatment of malignant pleural mesothelioma with the US FDA, citing strategic development and lifecycle management.
AI Analysis
Frequently Asked Questions
- Q: Why did the company withdraw the FDA application?
- A: To preserve flexibility for future development based on market and lifecycle strategy.